FAM193B: A Potential Drug Target and Biomarker (G54540)

Target Name: FAM193B

NCBI ID: G54540

FAM193B

FAM193B: A Potential Drug Target and Biomarker

FAM193B, also known as FAM193B-TIMP2, is a protein that is expressed in various tissues and organs, including the brain, heart, and pancreas. It is a key regulator of the TIMP2 complex, which is involved in the regulation of intracellular signaling pathways. In recent years, research has identified FAM193B as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The TIMP2 complex is a protein-protein interaction network that plays a crucial role in regulating various cellular processes, including cell signaling, DNA replication, and metabolism. The complex consists of four subunits: TIMP2, MAT2, MLC1, and RCS2. FAM193B is one of the subunits that belongs to the FAM193B family, which is characterized by the presence of a unique C-terminal region that contains a conserved catalytic site and a N-terminal region that is involved in protein-protein interactions.

FAM193B has been shown to play a critical role in the regulation of intracellular signaling pathways, including the TGF-β pathway. TGF-β is a well-known signaling pathway that is involved in various cellular processes, including cell growth, differentiation, and inflammation. The TGF-β pathway is a complex signaling pathway that is regulated by multiple proteins, including FAM193B.

In cancer, FAM193B has been shown to be involved in the regulation of the TGF-β pathway. Several studies have shown that FAM193B is a negative regulator of the TGF-β pathway, which means that it promotes the inhibition of TGF-β signaling. This is important because TGF-β signaling is often associated with the development and progression of cancer. Therefore, inhibiting FAM193B activity may be a potential strategy for cancer treatment.

In neurodegenerative diseases, FAM193B has been shown to be involved in the regulation of the TGF-β pathway. neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of progressive neuropathological changes. These diseases are often associated with the overuse of TGF-β, which may contribute to the development and progression of the disease. Therefore, targeting FAM193B activity may be a potential strategy for neurodegenerative disease treatment.

In autoimmune disorders, FAM193B has been shown to be involved in the regulation of the TGF-β pathway. Autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis, are characterized by the overactive immune system that leads to inflammation and tissue damage. The TGF-β pathway is often involved in the regulation of immune cell function, and therefore, alterations in FAM193B activity may be a potential strategy for treating autoimmune disorders.

In conclusion, FAM193B is a protein that has been shown to play a critical role in the regulation of various cellular processes, including intracellular signaling pathways. FAM193B has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, targeting FAM193B activity may be a promising strategy for the development of new therapeutic approaches for these diseases.

Protein Name: Family With Sequence Similarity 193 Member B

The "FAM193B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM193B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets